Clinical Edge Journal Scan

Key clinical point: Pretreatment calprotectin (MRP8/14) levels demonstrated no additional variability in predicting treatment response to tumor necrosis factor inhibitors (TNFis) beyond that of C-reactive protein (CRP) levels alone in patients with rheumatoid arthritis (RA).

Major finding: Higher vs lower pretreatment CRP levels predicted a good/moderate European League Against Rheumatism response at 3 months (odds ratio 3.79; P < .001), but MRP8/14 levels along with CRP levels offered no significant predictive improvement (P = .62). Unlike CRP level alone, pretreatment MRP8/14 level alone did not predict response to TNFi, as determined by Clinical Disease Activity Index (P = .839).

Study details: This post hoc analysis included 470 patients with RA whose serum MRP8/14 levels were measured before initiating adalimumab (n = 196) or etanercept (n = 274) treatment and after 3 months of adalimumab treatment (n = 179).

Disclosures: This study was supported by the UK National Institute for Health Research (NIHR) and other sources. Two authors declared being NIHR Senior investigators. Several authors reported ties with various sources unrelated to this study.

Source: Smith SL et al. Pre-treatment calprotectin (MRP8/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysis. Ann Rheum Dis. 2023 (Feb 21). Doi: 10.1136/ard-2022-222519

Key clinical point: Pretreatment calprotectin (MRP8/14) levels demonstrated no additional variability in predicting treatment response to tumor necrosis factor inhibitors (TNFis) beyond that of C-reactive protein (CRP) levels alone in patients with rheumatoid arthritis (RA).

Major finding: Higher vs lower pretreatment CRP levels predicted a good/moderate European League Against Rheumatism response at 3 months (odds ratio 3.79; P < .001), but MRP8/14 levels along with CRP levels offered no significant predictive improvement (P = .62). Unlike CRP level alone, pretreatment MRP8/14 level alone did not predict response to TNFi, as determined by Clinical Disease Activity Index (P = .839).

Study details: This post hoc analysis included 470 patients with RA whose serum MRP8/14 levels were measured before initiating adalimumab (n = 196) or etanercept (n = 274) treatment and after 3 months of adalimumab treatment (n = 179).

Disclosures: This study was supported by the UK National Institute for Health Research (NIHR) and other sources. Two authors declared being NIHR Senior investigators. Several authors reported ties with various sources unrelated to this study.

Source: Smith SL et al. Pre-treatment calprotectin (MRP8/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysis. Ann Rheum Dis. 2023 (Feb 21). Doi: 10.1136/ard-2022-222519

Key clinical point: Pretreatment calprotectin (MRP8/14) levels demonstrated no additional variability in predicting treatment response to tumor necrosis factor inhibitors (TNFis) beyond that of C-reactive protein (CRP) levels alone in patients with rheumatoid arthritis (RA).

Major finding: Higher vs lower pretreatment CRP levels predicted a good/moderate European League Against Rheumatism response at 3 months (odds ratio 3.79; P < .001), but MRP8/14 levels along with CRP levels offered no significant predictive improvement (P = .62). Unlike CRP level alone, pretreatment MRP8/14 level alone did not predict response to TNFi, as determined by Clinical Disease Activity Index (P = .839).

Study details: This post hoc analysis included 470 patients with RA whose serum MRP8/14 levels were measured before initiating adalimumab (n = 196) or etanercept (n = 274) treatment and after 3 months of adalimumab treatment (n = 179).

Disclosures: This study was supported by the UK National Institute for Health Research (NIHR) and other sources. Two authors declared being NIHR Senior investigators. Several authors reported ties with various sources unrelated to this study.

Source: Smith SL et al. Pre-treatment calprotectin (MRP8/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysis. Ann Rheum Dis. 2023 (Feb 21). Doi: 10.1136/ard-2022-222519

Key clinical point: A tight control strategy led to long-term remission in 31.5% of patients with rheumatoid arthritis (RA) in real-world practice, with certain clinical and demographic characteristics being independent predictors.

Major finding: Long-term remission was achieved by 31.5% of patients and was independently predicted by disease characteristics, such as absence of flare during disease course (odds ratio [OR] 15.12; P = .001), sustained remission at ≤6 months after starting therapy (OR 3.24; P = .001), and baseline Disease Activity Score in 28 joints of ≤5.1 (OR 2.36; P = .037). Other factors included demographic factors, such as age >60 years at disease onset (OR 2.71; P = .029), and being anticitrullinated protein antibody negative (OR 2.63; P = .008).

Study details: This longitudinal study included 499 patients with RA who were treated with a tight control strategy, including step-up combination therapy with conventional synthetic and biologic disease-modifying antirheumatic drugs.

Disclosures: This study did not report the funding source or any conflicts of interest.

Source: Khabbazi A et al. Prevalence and predictors of long-term remission in rheumatoid arthritis in real-world practice: A longitudinal study. Clin Rheumatol. 2023 (Feb 17). Doi: 10.1007/s10067-023-06548-1

Key clinical point: A tight control strategy led to long-term remission in 31.5% of patients with rheumatoid arthritis (RA) in real-world practice, with certain clinical and demographic characteristics being independent predictors.

Major finding: Long-term remission was achieved by 31.5% of patients and was independently predicted by disease characteristics, such as absence of flare during disease course (odds ratio [OR] 15.12; P = .001), sustained remission at ≤6 months after starting therapy (OR 3.24; P = .001), and baseline Disease Activity Score in 28 joints of ≤5.1 (OR 2.36; P = .037). Other factors included demographic factors, such as age >60 years at disease onset (OR 2.71; P = .029), and being anticitrullinated protein antibody negative (OR 2.63; P = .008).

Study details: This longitudinal study included 499 patients with RA who were treated with a tight control strategy, including step-up combination therapy with conventional synthetic and biologic disease-modifying antirheumatic drugs.

Disclosures: This study did not report the funding source or any conflicts of interest.

Source: Khabbazi A et al. Prevalence and predictors of long-term remission in rheumatoid arthritis in real-world practice: A longitudinal study. Clin Rheumatol. 2023 (Feb 17). Doi: 10.1007/s10067-023-06548-1

Key clinical point: A tight control strategy led to long-term remission in 31.5% of patients with rheumatoid arthritis (RA) in real-world practice, with certain clinical and demographic characteristics being independent predictors.

Major finding: Long-term remission was achieved by 31.5% of patients and was independently predicted by disease characteristics, such as absence of flare during disease course (odds ratio [OR] 15.12; P = .001), sustained remission at ≤6 months after starting therapy (OR 3.24; P = .001), and baseline Disease Activity Score in 28 joints of ≤5.1 (OR 2.36; P = .037). Other factors included demographic factors, such as age >60 years at disease onset (OR 2.71; P = .029), and being anticitrullinated protein antibody negative (OR 2.63; P = .008).

Study details: This longitudinal study included 499 patients with RA who were treated with a tight control strategy, including step-up combination therapy with conventional synthetic and biologic disease-modifying antirheumatic drugs.

Disclosures: This study did not report the funding source or any conflicts of interest.

Source: Khabbazi A et al. Prevalence and predictors of long-term remission in rheumatoid arthritis in real-world practice: A longitudinal study. Clin Rheumatol. 2023 (Feb 17). Doi: 10.1007/s10067-023-06548-1

Key clinical point: Menopause at an early vs usual age (<45 vs ≥45 years) was associated with a higher disease activity and worse patient-reported outcomes in postmenopausal women with rheumatoid arthritis (RA).

Major finding: At baseline, women with early vs usual menopause had significantly higher Disease Activity Score in 28 joints (DAS28; P = .018) and Visual Analogue Scale (VAS) scores for global assessment (P = .016) and fatigue (P = .005), along with worse EuroQol-5D-VAS scores (P = .006). Early menopause was significantly associated with increased DAS28 (regression coefficient [β] 0.178; P = .013) and decreased EuroQol-5D utility values (β −0.033; P = .016) at 5-year follow-up.

Study details: This prospective observational cohort study included 2878 postmenopausal women with RA who had menopause at an early (n = 437) or usual (n = 2441) age.

Disclosures: This study was supported by Chung-Ang University research grants in 2022 and the National Research Foundation of Korea grant funded by the Korean government. The authors did not declare conflicts of interest.

Source: Park EH et al. Impact of early age at menopause on disease outcomes in postmenopausal women with rheumatoid arthritis: A large observational cohort study of Korean patients with rheumatoid arthritis. RMD Open. 2023;9:e002722 (Feb 15). Doi: 10.1136/rmdopen-2022-002722

Key clinical point: Menopause at an early vs usual age (<45 vs ≥45 years) was associated with a higher disease activity and worse patient-reported outcomes in postmenopausal women with rheumatoid arthritis (RA).

Major finding: At baseline, women with early vs usual menopause had significantly higher Disease Activity Score in 28 joints (DAS28; P = .018) and Visual Analogue Scale (VAS) scores for global assessment (P = .016) and fatigue (P = .005), along with worse EuroQol-5D-VAS scores (P = .006). Early menopause was significantly associated with increased DAS28 (regression coefficient [β] 0.178; P = .013) and decreased EuroQol-5D utility values (β −0.033; P = .016) at 5-year follow-up.

Study details: This prospective observational cohort study included 2878 postmenopausal women with RA who had menopause at an early (n = 437) or usual (n = 2441) age.

Disclosures: This study was supported by Chung-Ang University research grants in 2022 and the National Research Foundation of Korea grant funded by the Korean government. The authors did not declare conflicts of interest.

Source: Park EH et al. Impact of early age at menopause on disease outcomes in postmenopausal women with rheumatoid arthritis: A large observational cohort study of Korean patients with rheumatoid arthritis. RMD Open. 2023;9:e002722 (Feb 15). Doi: 10.1136/rmdopen-2022-002722

Key clinical point: Menopause at an early vs usual age (<45 vs ≥45 years) was associated with a higher disease activity and worse patient-reported outcomes in postmenopausal women with rheumatoid arthritis (RA).

Major finding: At baseline, women with early vs usual menopause had significantly higher Disease Activity Score in 28 joints (DAS28; P = .018) and Visual Analogue Scale (VAS) scores for global assessment (P = .016) and fatigue (P = .005), along with worse EuroQol-5D-VAS scores (P = .006). Early menopause was significantly associated with increased DAS28 (regression coefficient [β] 0.178; P = .013) and decreased EuroQol-5D utility values (β −0.033; P = .016) at 5-year follow-up.

Study details: This prospective observational cohort study included 2878 postmenopausal women with RA who had menopause at an early (n = 437) or usual (n = 2441) age.

Disclosures: This study was supported by Chung-Ang University research grants in 2022 and the National Research Foundation of Korea grant funded by the Korean government. The authors did not declare conflicts of interest.

Source: Park EH et al. Impact of early age at menopause on disease outcomes in postmenopausal women with rheumatoid arthritis: A large observational cohort study of Korean patients with rheumatoid arthritis. RMD Open. 2023;9:e002722 (Feb 15). Doi: 10.1136/rmdopen-2022-002722

Key clinical point: Computed tomography (CT) screening before initiating biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARD) in patients with rheumatoid arthritis (RA) may help in early detection and treatment of malignancies, resulting in a safer and more stable RA treatment course.

Major finding: Malignancy was confirmed in 33 patients; however, only 7 vs 33 cases were detected with regular vs CT screening, respectively. Overall, 6 of 7 cases detected by regular screening were progressed stage malignancies, whereas 19 of 33 cases detected by CT screening were early stage malignancies; 80% of patients diagnosed with early stage malignancy achieved low-disease activity after 1 year of RA treatment.

Study details: This study evaluated 2192 patients with RA who were screened for malignancy using regular physical examination followed by CT before initiating b/tsDMARD.

Disclosures: This study was partly supported by the University of Occupational and Environmental Health, Japan. Five authors declared receiving research grants, consulting fees, lecture fees, speaking fees, or honoraria from various sources.

Source: Miyata H et al. Computed tomography for malignancy screening in patients with rheumatoid arthritis before initiation of disease modifying antirheumatic drug. Rheumatology (Oxford). 2023 (Feb 14). Doi: 10.1093/rheumatology/kead075

Key clinical point: Computed tomography (CT) screening before initiating biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARD) in patients with rheumatoid arthritis (RA) may help in early detection and treatment of malignancies, resulting in a safer and more stable RA treatment course.

Major finding: Malignancy was confirmed in 33 patients; however, only 7 vs 33 cases were detected with regular vs CT screening, respectively. Overall, 6 of 7 cases detected by regular screening were progressed stage malignancies, whereas 19 of 33 cases detected by CT screening were early stage malignancies; 80% of patients diagnosed with early stage malignancy achieved low-disease activity after 1 year of RA treatment.

Study details: This study evaluated 2192 patients with RA who were screened for malignancy using regular physical examination followed by CT before initiating b/tsDMARD.

Disclosures: This study was partly supported by the University of Occupational and Environmental Health, Japan. Five authors declared receiving research grants, consulting fees, lecture fees, speaking fees, or honoraria from various sources.

Source: Miyata H et al. Computed tomography for malignancy screening in patients with rheumatoid arthritis before initiation of disease modifying antirheumatic drug. Rheumatology (Oxford). 2023 (Feb 14). Doi: 10.1093/rheumatology/kead075

Key clinical point: Computed tomography (CT) screening before initiating biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARD) in patients with rheumatoid arthritis (RA) may help in early detection and treatment of malignancies, resulting in a safer and more stable RA treatment course.

Major finding: Malignancy was confirmed in 33 patients; however, only 7 vs 33 cases were detected with regular vs CT screening, respectively. Overall, 6 of 7 cases detected by regular screening were progressed stage malignancies, whereas 19 of 33 cases detected by CT screening were early stage malignancies; 80% of patients diagnosed with early stage malignancy achieved low-disease activity after 1 year of RA treatment.

Study details: This study evaluated 2192 patients with RA who were screened for malignancy using regular physical examination followed by CT before initiating b/tsDMARD.

Disclosures: This study was partly supported by the University of Occupational and Environmental Health, Japan. Five authors declared receiving research grants, consulting fees, lecture fees, speaking fees, or honoraria from various sources.

Source: Miyata H et al. Computed tomography for malignancy screening in patients with rheumatoid arthritis before initiation of disease modifying antirheumatic drug. Rheumatology (Oxford). 2023 (Feb 14). Doi: 10.1093/rheumatology/kead075

Key clinical point: Rheumatoid arthritis (RA) reduced survival rates and increased the risk for long-term major adverse cardiovascular events (MACE) in patients with ischemic heart disease who underwent percutaneous coronary intervention (PCI); however, RA had no influence over short-term MACE.

Major finding: Patients with vs without RA who underwent PCI had lower survival rates (log-rank P < .001) and were at a significantly higher risk for long-term MACE (adjusted hazard ratio 1.07; P < .001), although the risk for short-term MACE was not significantly different between both the cohorts (P = .222).

Study details: This retrospective cohort study included 236,134 patients who underwent PCI, of which 34,493 patients had RA.

Disclosures: This study was supported by the Medical Research Promotion Program of Gangneung Asan Hospital, funded by the Asan Foundation, South Korea. The authors declared no conflicts of interest.

Source: Ha SJ et al. Clinical outcomes of patients with rheumatoid arthritis who underwent percutaneous coronary intervention: A Korean nationwide cohort study. PLoS One. 2023;18(2):e0281067 (Feb 14). Doi: 10.1371/journal.pone.0281067

Key clinical point: Rheumatoid arthritis (RA) reduced survival rates and increased the risk for long-term major adverse cardiovascular events (MACE) in patients with ischemic heart disease who underwent percutaneous coronary intervention (PCI); however, RA had no influence over short-term MACE.

Major finding: Patients with vs without RA who underwent PCI had lower survival rates (log-rank P < .001) and were at a significantly higher risk for long-term MACE (adjusted hazard ratio 1.07; P < .001), although the risk for short-term MACE was not significantly different between both the cohorts (P = .222).

Study details: This retrospective cohort study included 236,134 patients who underwent PCI, of which 34,493 patients had RA.

Disclosures: This study was supported by the Medical Research Promotion Program of Gangneung Asan Hospital, funded by the Asan Foundation, South Korea. The authors declared no conflicts of interest.

Source: Ha SJ et al. Clinical outcomes of patients with rheumatoid arthritis who underwent percutaneous coronary intervention: A Korean nationwide cohort study. PLoS One. 2023;18(2):e0281067 (Feb 14). Doi: 10.1371/journal.pone.0281067

Key clinical point: Rheumatoid arthritis (RA) reduced survival rates and increased the risk for long-term major adverse cardiovascular events (MACE) in patients with ischemic heart disease who underwent percutaneous coronary intervention (PCI); however, RA had no influence over short-term MACE.

Major finding: Patients with vs without RA who underwent PCI had lower survival rates (log-rank P < .001) and were at a significantly higher risk for long-term MACE (adjusted hazard ratio 1.07; P < .001), although the risk for short-term MACE was not significantly different between both the cohorts (P = .222).

Study details: This retrospective cohort study included 236,134 patients who underwent PCI, of which 34,493 patients had RA.

Disclosures: This study was supported by the Medical Research Promotion Program of Gangneung Asan Hospital, funded by the Asan Foundation, South Korea. The authors declared no conflicts of interest.

Source: Ha SJ et al. Clinical outcomes of patients with rheumatoid arthritis who underwent percutaneous coronary intervention: A Korean nationwide cohort study. PLoS One. 2023;18(2):e0281067 (Feb 14). Doi: 10.1371/journal.pone.0281067

Key clinical point: Younger patients and patients with higher disability scores at early stages were more likely to develop difficult-to-treat rheumatoid arthritis (RA). Thus focusing on severe disability during initial stages may alter disease course.

Major finding: Elevated initial disability score (odds ratio [OR] 1.89; P = .01) and a younger age at baseline (OR 0.95; P = .01) were associated with an increased risk for difficult-to-treat RA, whereas initial disease activity failed to show any influence.

Study details: The data come from a longitudinal, prospective cohort study including 631 patients with newly diagnosed RA, of which 35 patients developed difficult-to-treat RA.

Disclosures: This study was supported by the Instituto de Salud Carlos III, Spain, and other sources. The authors did not declare any conflicts of interest.

Source: Leon L et al. Difficult-to-treat rheumatoid arthritis (D2T RA): Clinical issues at early stages of disease. RMD Open. 2023;9:e002842 (Mar 8). Doi: 10.1136/rmdopen-2022-002842

Key clinical point: Younger patients and patients with higher disability scores at early stages were more likely to develop difficult-to-treat rheumatoid arthritis (RA). Thus focusing on severe disability during initial stages may alter disease course.

Major finding: Elevated initial disability score (odds ratio [OR] 1.89; P = .01) and a younger age at baseline (OR 0.95; P = .01) were associated with an increased risk for difficult-to-treat RA, whereas initial disease activity failed to show any influence.

Study details: The data come from a longitudinal, prospective cohort study including 631 patients with newly diagnosed RA, of which 35 patients developed difficult-to-treat RA.

Disclosures: This study was supported by the Instituto de Salud Carlos III, Spain, and other sources. The authors did not declare any conflicts of interest.

Source: Leon L et al. Difficult-to-treat rheumatoid arthritis (D2T RA): Clinical issues at early stages of disease. RMD Open. 2023;9:e002842 (Mar 8). Doi: 10.1136/rmdopen-2022-002842

Key clinical point: Younger patients and patients with higher disability scores at early stages were more likely to develop difficult-to-treat rheumatoid arthritis (RA). Thus focusing on severe disability during initial stages may alter disease course.

Major finding: Elevated initial disability score (odds ratio [OR] 1.89; P = .01) and a younger age at baseline (OR 0.95; P = .01) were associated with an increased risk for difficult-to-treat RA, whereas initial disease activity failed to show any influence.

Study details: The data come from a longitudinal, prospective cohort study including 631 patients with newly diagnosed RA, of which 35 patients developed difficult-to-treat RA.

Disclosures: This study was supported by the Instituto de Salud Carlos III, Spain, and other sources. The authors did not declare any conflicts of interest.

Source: Leon L et al. Difficult-to-treat rheumatoid arthritis (D2T RA): Clinical issues at early stages of disease. RMD Open. 2023;9:e002842 (Mar 8). Doi: 10.1136/rmdopen-2022-002842

Key clinical point: A nearly 50% reduction in methotrexate dose at the time of initiating a tumor necrosis factor inhibitor (TNFi) is possible in patients with rheumatoid arthritis (RA) who had an inadequate response to the initial maximum tolerated dose of methotrexate.

Major finding: Reduced-dose methotrexate+adalimumab was noninferior to maximal-dose methotrexate+adalimumab in achieving Simplified Disease Activity Index-based remission at week 48 (adjusted risk difference 6.4%; 90% CI −7.0% to 19.8%) and less frequently caused adverse events after 24 weeks (20% vs 35%). No deaths were reported.

Study details: Findings are from the MIRACLE trial including 291 methotrexate-naive patients with RA and inadequate response to the maximum tolerated methotrexate dose who were randomly assigned to initiate adalimumab in combination with the maximum tolerated dose or a reduced dose of methotrexate.

Disclosures: This study was funded by Eisai. Three authors declared being employees and shareholders of Eisai. Several authors declared receiving speaker honoraria, grants, research support, consulting fees, or royalties from Eisai and other sources.

Source: Tamai H et al and MIRACLE study collaborators. Reduced versus maximum tolerated methotrexate dose concomitant with adalimumab in patients with rheumatoid arthritis (MIRACLE): A randomised, open-label, non-inferiority trial. Lancet Rheumatol. 2023;5(4):E215-E224 (Apr). Doi: 10.1016/S2665-9913(23)00070-X

Key clinical point: A nearly 50% reduction in methotrexate dose at the time of initiating a tumor necrosis factor inhibitor (TNFi) is possible in patients with rheumatoid arthritis (RA) who had an inadequate response to the initial maximum tolerated dose of methotrexate.

Major finding: Reduced-dose methotrexate+adalimumab was noninferior to maximal-dose methotrexate+adalimumab in achieving Simplified Disease Activity Index-based remission at week 48 (adjusted risk difference 6.4%; 90% CI −7.0% to 19.8%) and less frequently caused adverse events after 24 weeks (20% vs 35%). No deaths were reported.

Study details: Findings are from the MIRACLE trial including 291 methotrexate-naive patients with RA and inadequate response to the maximum tolerated methotrexate dose who were randomly assigned to initiate adalimumab in combination with the maximum tolerated dose or a reduced dose of methotrexate.

Disclosures: This study was funded by Eisai. Three authors declared being employees and shareholders of Eisai. Several authors declared receiving speaker honoraria, grants, research support, consulting fees, or royalties from Eisai and other sources.

Source: Tamai H et al and MIRACLE study collaborators. Reduced versus maximum tolerated methotrexate dose concomitant with adalimumab in patients with rheumatoid arthritis (MIRACLE): A randomised, open-label, non-inferiority trial. Lancet Rheumatol. 2023;5(4):E215-E224 (Apr). Doi: 10.1016/S2665-9913(23)00070-X

Key clinical point: A nearly 50% reduction in methotrexate dose at the time of initiating a tumor necrosis factor inhibitor (TNFi) is possible in patients with rheumatoid arthritis (RA) who had an inadequate response to the initial maximum tolerated dose of methotrexate.

Major finding: Reduced-dose methotrexate+adalimumab was noninferior to maximal-dose methotrexate+adalimumab in achieving Simplified Disease Activity Index-based remission at week 48 (adjusted risk difference 6.4%; 90% CI −7.0% to 19.8%) and less frequently caused adverse events after 24 weeks (20% vs 35%). No deaths were reported.

Study details: Findings are from the MIRACLE trial including 291 methotrexate-naive patients with RA and inadequate response to the maximum tolerated methotrexate dose who were randomly assigned to initiate adalimumab in combination with the maximum tolerated dose or a reduced dose of methotrexate.

Disclosures: This study was funded by Eisai. Three authors declared being employees and shareholders of Eisai. Several authors declared receiving speaker honoraria, grants, research support, consulting fees, or royalties from Eisai and other sources.

Source: Tamai H et al and MIRACLE study collaborators. Reduced versus maximum tolerated methotrexate dose concomitant with adalimumab in patients with rheumatoid arthritis (MIRACLE): A randomised, open-label, non-inferiority trial. Lancet Rheumatol. 2023;5(4):E215-E224 (Apr). Doi: 10.1016/S2665-9913(23)00070-X

Key clinical point: The risk for a second primary malignancy (SPM) was higher in patients with indolent B‐cell lymphoma (iBCL) treated with bendamustine/rituximab (BR) vs rituximab monotherapy and rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP) or rituximab, cyclophosphamide, vincristine, and prednisone (RCVP) or rituximab, pirarubicin, cyclophosphamide, vincristine, and prednisolone (RTHPCOP).

Major finding: The cumulative incidence of SPM was significantly higher among patients receiving BR vs rituximab monotherapy (P < .01) or RCHOP/RCVP/RTHPCOP (P < .0001). The 5‐year cumulative incidence rates with BR, rituximab monotherapy, and RCHOP/RCVP/RTHPCOP were 18.1%, 12.5%, and 12.9%, respectively.

Study details: This retrospective observational study included 5234 adult patients with iBCL who received rituximab monotherapy (n = 780), RCHOP/RCVP/RTHPCOP (n = 2298), or BR (n = 2156).

Disclosures: This study was supported by the Japan Society for the Promotion of Science. Y Muraki declared receiving a lecture honorarium from Pfizer Japan, Inc.

Source: Dote S et al. Risk of a second cancer and infection in patients with indolent B-cell lymphoma exposed to first-line bendamustine plus rituximab: A retrospective analysis of an administrative claims database. Hematol Oncol. 2023 (Feb 15). Doi: 10.1002/hon.3128.

Key clinical point: The risk for a second primary malignancy (SPM) was higher in patients with indolent B‐cell lymphoma (iBCL) treated with bendamustine/rituximab (BR) vs rituximab monotherapy and rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP) or rituximab, cyclophosphamide, vincristine, and prednisone (RCVP) or rituximab, pirarubicin, cyclophosphamide, vincristine, and prednisolone (RTHPCOP).

Major finding: The cumulative incidence of SPM was significantly higher among patients receiving BR vs rituximab monotherapy (P < .01) or RCHOP/RCVP/RTHPCOP (P < .0001). The 5‐year cumulative incidence rates with BR, rituximab monotherapy, and RCHOP/RCVP/RTHPCOP were 18.1%, 12.5%, and 12.9%, respectively.

Study details: This retrospective observational study included 5234 adult patients with iBCL who received rituximab monotherapy (n = 780), RCHOP/RCVP/RTHPCOP (n = 2298), or BR (n = 2156).

Disclosures: This study was supported by the Japan Society for the Promotion of Science. Y Muraki declared receiving a lecture honorarium from Pfizer Japan, Inc.

Source: Dote S et al. Risk of a second cancer and infection in patients with indolent B-cell lymphoma exposed to first-line bendamustine plus rituximab: A retrospective analysis of an administrative claims database. Hematol Oncol. 2023 (Feb 15). Doi: 10.1002/hon.3128.

Key clinical point: The risk for a second primary malignancy (SPM) was higher in patients with indolent B‐cell lymphoma (iBCL) treated with bendamustine/rituximab (BR) vs rituximab monotherapy and rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP) or rituximab, cyclophosphamide, vincristine, and prednisone (RCVP) or rituximab, pirarubicin, cyclophosphamide, vincristine, and prednisolone (RTHPCOP).

Major finding: The cumulative incidence of SPM was significantly higher among patients receiving BR vs rituximab monotherapy (P < .01) or RCHOP/RCVP/RTHPCOP (P < .0001). The 5‐year cumulative incidence rates with BR, rituximab monotherapy, and RCHOP/RCVP/RTHPCOP were 18.1%, 12.5%, and 12.9%, respectively.

Study details: This retrospective observational study included 5234 adult patients with iBCL who received rituximab monotherapy (n = 780), RCHOP/RCVP/RTHPCOP (n = 2298), or BR (n = 2156).

Disclosures: This study was supported by the Japan Society for the Promotion of Science. Y Muraki declared receiving a lecture honorarium from Pfizer Japan, Inc.

Source: Dote S et al. Risk of a second cancer and infection in patients with indolent B-cell lymphoma exposed to first-line bendamustine plus rituximab: A retrospective analysis of an administrative claims database. Hematol Oncol. 2023 (Feb 15). Doi: 10.1002/hon.3128.

Key clinical point: Multimodal treatment comprising total body irradiation (TBI), high-dose chemotherapy, and autologous stem cell transplantation (autoSCT) offers long-term survival in patients with mantle cell lymphoma (MCL).

Major finding: The median overall survival of patients who underwent TBI and autoSCT was 11.4 years, whereas that of patients who underwent TBI and allogenic stem cell transplantation (alloSCT) was 3.25 years. Compared with the whole cohort, patients receiving autoSCT presented a better overall survival rate (50.0% vs 57.9%) after reaching a plateau at 6.8 years.

Study details: Findings are from a single-center retrospective study including 22 patients with advanced MCL who underwent TBI before autoSCT (n = 19) or alloSCT (n = 3).

Disclosures: This study received no external funding. The authors declared no conflict on interests.

Source: Kröger K et al. Long-term survival of patients with mantle cell lymphoma after total body irradiation, high-dose chemotherapy and stem cell transplantation: A monocenter study. Cancers (Basel). 2023;15(3):983 (Feb 3). Doi: 10.3390/cancers15030983

Key clinical point: Multimodal treatment comprising total body irradiation (TBI), high-dose chemotherapy, and autologous stem cell transplantation (autoSCT) offers long-term survival in patients with mantle cell lymphoma (MCL).

Major finding: The median overall survival of patients who underwent TBI and autoSCT was 11.4 years, whereas that of patients who underwent TBI and allogenic stem cell transplantation (alloSCT) was 3.25 years. Compared with the whole cohort, patients receiving autoSCT presented a better overall survival rate (50.0% vs 57.9%) after reaching a plateau at 6.8 years.

Study details: Findings are from a single-center retrospective study including 22 patients with advanced MCL who underwent TBI before autoSCT (n = 19) or alloSCT (n = 3).

Disclosures: This study received no external funding. The authors declared no conflict on interests.

Source: Kröger K et al. Long-term survival of patients with mantle cell lymphoma after total body irradiation, high-dose chemotherapy and stem cell transplantation: A monocenter study. Cancers (Basel). 2023;15(3):983 (Feb 3). Doi: 10.3390/cancers15030983

Key clinical point: Multimodal treatment comprising total body irradiation (TBI), high-dose chemotherapy, and autologous stem cell transplantation (autoSCT) offers long-term survival in patients with mantle cell lymphoma (MCL).

Major finding: The median overall survival of patients who underwent TBI and autoSCT was 11.4 years, whereas that of patients who underwent TBI and allogenic stem cell transplantation (alloSCT) was 3.25 years. Compared with the whole cohort, patients receiving autoSCT presented a better overall survival rate (50.0% vs 57.9%) after reaching a plateau at 6.8 years.

Study details: Findings are from a single-center retrospective study including 22 patients with advanced MCL who underwent TBI before autoSCT (n = 19) or alloSCT (n = 3).

Disclosures: This study received no external funding. The authors declared no conflict on interests.

Source: Kröger K et al. Long-term survival of patients with mantle cell lymphoma after total body irradiation, high-dose chemotherapy and stem cell transplantation: A monocenter study. Cancers (Basel). 2023;15(3):983 (Feb 3). Doi: 10.3390/cancers15030983

Key clinical point: Only the copresence of TP53 deletion (del17p) and mutations and not a single aberration has a negative prognostic impact in patients with chronic lymphocytic leukemia (CLL) receiving ibrutinib treatment.

Major finding: Only patients with concomitant TP53 mutations and del17p had significantly shorter overall survival (OS; P = .0073) and progression-free survival (PFS; P = .0037) than those with no TP53 aberration; no difference in OS or PFS was observed in patients with single aberration. TP53 mutation and del17p copresence was an independent predictor for short OS and PFS (adjusted hazard ratio 2.27; P = .0077).

Study details: This multicenter retrospective study included 229 patients with CLL treated with ibrutinib who were assayed for TP53 mutation and del17p in the same blood sample that was collected within 6 months before initiating ibrutinib.

Disclosures: This study was supported in part by the Italian Ministry of Health “Progetto Ricerca Finalizzata” and others. The authors declared no conflicts of interest.

Source: Bomben R et al. Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: A campus CLL study. Leukemia. 2023 (Feb 18). Doi: 10.1038/s41375-023-01845-9

Key clinical point: Only the copresence of TP53 deletion (del17p) and mutations and not a single aberration has a negative prognostic impact in patients with chronic lymphocytic leukemia (CLL) receiving ibrutinib treatment.

Major finding: Only patients with concomitant TP53 mutations and del17p had significantly shorter overall survival (OS; P = .0073) and progression-free survival (PFS; P = .0037) than those with no TP53 aberration; no difference in OS or PFS was observed in patients with single aberration. TP53 mutation and del17p copresence was an independent predictor for short OS and PFS (adjusted hazard ratio 2.27; P = .0077).

Study details: This multicenter retrospective study included 229 patients with CLL treated with ibrutinib who were assayed for TP53 mutation and del17p in the same blood sample that was collected within 6 months before initiating ibrutinib.

Disclosures: This study was supported in part by the Italian Ministry of Health “Progetto Ricerca Finalizzata” and others. The authors declared no conflicts of interest.

Source: Bomben R et al. Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: A campus CLL study. Leukemia. 2023 (Feb 18). Doi: 10.1038/s41375-023-01845-9

Key clinical point: Only the copresence of TP53 deletion (del17p) and mutations and not a single aberration has a negative prognostic impact in patients with chronic lymphocytic leukemia (CLL) receiving ibrutinib treatment.

Major finding: Only patients with concomitant TP53 mutations and del17p had significantly shorter overall survival (OS; P = .0073) and progression-free survival (PFS; P = .0037) than those with no TP53 aberration; no difference in OS or PFS was observed in patients with single aberration. TP53 mutation and del17p copresence was an independent predictor for short OS and PFS (adjusted hazard ratio 2.27; P = .0077).

Study details: This multicenter retrospective study included 229 patients with CLL treated with ibrutinib who were assayed for TP53 mutation and del17p in the same blood sample that was collected within 6 months before initiating ibrutinib.

Disclosures: This study was supported in part by the Italian Ministry of Health “Progetto Ricerca Finalizzata” and others. The authors declared no conflicts of interest.

Source: Bomben R et al. Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: A campus CLL study. Leukemia. 2023 (Feb 18). Doi: 10.1038/s41375-023-01845-9